The ODX share price jumps! Should I buy the stock?

The ODX share price has been on a tear over the past 12 months, but the question is, can the company continue this performance?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The ODX (LSE: ODX) share price has rocketed in recent weeks. Over the past four months, shares in the diagnostics and testing business have increased in value by more than 80%. Over the past 12 months, the stock has increased in value by nearly 600%.  

The company’s longer-term performance is a bit more sedate. The ODX share price bumbled along at a price of between 15p to 20p between the beginning of 2016 and March of 2020.

However, when the pandemic struck, its fortunes began to change. It has offered its experience in the testing and diagnostic space to help the government’s testing programme. ODX had planned to produce as many as five different types of Covid-19 tests

And today, the firm has announced that it has agreed a contract with the UK Department of Health and Social Care (DHSC) to provide manufacturing capacity for Covid-19 lateral flow antigen tests.

A new deal 

The company hasn’t said how much of an impact this agreement will have on its future potential. Nevertheless, management has disclosed that the deal could provide a “significant contribution” to future performance.

There’s no doubt this is a massive deal for the firm. ODX anticipates it will be able to produce approximately two million tests per week by the end of April. Production can begin as soon as the DHSC has a test that has passed performance and regulatory hurdles. 

There’s no doubt in my mind this is a tremendous opportunity for the company. Still, I think it’s challenging to place a value on the ODX share price right now. According to its latest figures, full-year group revenue for its current financial year is expected to be £9.3m.

Management believes the organisation will report earnings before interest tax depreciation and amortisation (EBITDA) loss of around £2.1m-£2.3m on this figure. 

How much is the ODX share price worth? 

Next year, the company expects to deliver “substantial revenue growth compared to this financial year.” Management also sees tremendous opportunities in the group’s legacy food intolerance testing business alongside its Covid-19 testing division.

As the financial terms of the latest deal with the DHSC haven’t been disclosed, it’s difficult at this stage to tell how much of an impact this will have on ODX’s revenue growth next year.

Based on what we do know, City analysts have pencilled in revenues of £12.6m for its 2021 financial year, and £14.7m for 2022. This could translate into earnings per share of around 0.9p. I should caution that these are just forecasts at this stage.

There’s no guarantee the company will meet these targets. Equally, it could surpass these growth projections. 

Still, looking at its current market capitalisation of £170m, I think the ODX share price might have gotten ahead of itself in recent weeks. The company’s future is highly uncertain, and we don’t know how much of an impact the latest deal will have on its bottom line at this point. 

Therefore, while the City expects big things from the business in the next two years, ODX’s current valuation makes me uneasy. I’m not a buyer of the shares at current levels as a result. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »